MBAL Sveta Marina EAD

The Clinic of Gastroenterology at MBAL Sveta Marina is actively exploring new treatments for cardiovascular disease, aiming to lower the risk of heart attacks, strokes, and related events while improving blood pressure control.

• Evaluation of a novel peptide therapy to reduce major adverse cardiovascular events in high‑risk patients
• Assessment of an antihypertensive agent in individuals with uncontrolled hypertension
• Investigation of renal‑protective strategies in patients with chronic kidney disease and cardiovascular risk

The site’s multidisciplinary team collaborates closely with cardiology specialists to bring innovative solutions to everyday practice.

Research at the Varna location includes studies on blood‑related cancers, focusing on therapies that enhance survival and quality of life for patients with chronic lymphocytic leukemia and related disorders.

• Study of a B‑cell targeting agent in previously treated chronic lymphocytic leukemia
• Combination immunotherapy trial for advanced urothelial cancer
• Safety assessment of novel agents in small lymphocytic lymphoma

Oncology experts at MBAL Sveta Marina provide comprehensive care and support throughout trial participation.

The department conducts trials aimed at children with growth challenges, evaluating alternatives to daily injections for conditions such as short stature due to Turner syndrome, small for gestational age, Noonan syndrome, or idiopathic causes.

• Comparison of weekly somapacitan versus daily growth hormone therapy
• Growth velocity monitoring over a 12‑month period
• Safety and tolerability assessment in pediatric participants

These studies help families access more convenient treatment options while maintaining effective growth outcomes.

Investigations target autoimmune conditions, seeking to modulate the immune response in diseases such as Sjögren's disease, multiple sclerosis, and post‑herpetic neuralgia.

• Evaluation of an anti‑B‑cell antibody in moderate to severe Sjögren's disease
• Testing a novel oral agent to delay relapses in relapsing‑remitting multiple sclerosis
• Dose‑finding study of a new analgesic for post‑herpetic neuralgia pain relief

The clinic’s immunology expertise supports the development of therapies that aim to restore immune balance.

Oncology trials at the site address solid tumors, including efforts to improve outcomes for patients with colorectal cancer and advanced bladder malignancies.

• Assessment of a targeted therapy combined with standard chemotherapy in metastatic urothelial cancer
• Investigation of an agent designed to alleviate cancer cachexia in colorectal cancer patients
• Safety monitoring of immune checkpoint inhibitors in advanced bladder cancer

MBAL Sveta Marina collaborates with regional cancer centers to bring cutting‑edge treatments to patients.

The clinic’s neurology research focuses on disease‑modifying strategies for multiple sclerosis and pain syndromes such as post‑herpetic neuralgia.

• Phase‑2 trial of an oral compound to reduce brain atrophy in progressive multiple sclerosis
• Study of a novel therapy to delay first relapse in relapsing‑remitting multiple sclerosis
• Evaluation of a new analgesic formulation for persistent post‑herpetic neuralgia pain

These projects aim to preserve neurological function and improve daily living for affected individuals.

Trials in this area explore interventions for obesity, type 2 diabetes, and related metabolic disorders, seeking effective weight‑management and glycemic‑control solutions.

• Evaluation of a dual‑agonist peptide for weight reduction in adults with obesity
• Study of a novel agent to lower blood pressure and cardiovascular risk in hypertensive patients
• Safety and tolerability assessment of a metabolic drug in participants with obesity and type 2 diabetes

The research supports the development of therapies that address both weight and metabolic health.

The site participates in antiviral investigations, notably for chronic infections such as hepatitis delta, aiming to improve viral suppression and liver health.

• First‑in‑human safety and pharmacokinetic study of a novel antiviral compound
• Efficacy evaluation of the same compound in patients with chronic hepatitis delta infection
• Long‑term safety monitoring for liver function and viral load reduction

Collaboration with virology experts ensures rigorous assessment of emerging treatments.

In addition to disease‑specific studies, MBAL Sveta Marina supports exploratory projects that span multiple therapeutic categories, focusing on innovative mechanisms and patient‑centered outcomes.

• Cross‑disciplinary safety assessments of new molecular entities
• Biomarker discovery programs to personalize therapy selection
• Patient‑reported outcome measures to evaluate quality of life across conditions

These overarching efforts complement the site’s targeted trials and enhance overall clinical research capacity.